# Clinical Trial: NCT_HYPERTENSION_002

## Study Title
A Phase 3 Study to Evaluate Efficacy of Novel Antihypertensive Agent ABC in Essential Hypertension

## Protocol Version
Version 2.0 - December 2024

## Sponsor
CardioPharm Research

## Study Phase
Phase 3

## Target Condition
Essential Hypertension

---

## INCLUSION CRITERIA

Patients must meet ALL of the following criteria to be eligible:

1. **Age Requirement**
   - Age 30-80 years at the time of informed consent

2. **Hypertension Diagnosis**
   - Essential hypertension confirmed by sitting blood pressure measurements
   - Systolic BP ≥140 mmHg and/or Diastolic BP ≥90 mmHg at screening
   - Currently on 1-3 antihypertensive medications with stable doses for ≥4 weeks

3. **Blood Pressure Range**
   - Sitting SBP: 140-180 mmHg
   - Sitting DBP: 90-110 mmHg

4. **Renal Function**
   - eGFR ≥30 mL/min/1.73m² using CKD-EPI equation

5. **Informed Consent**
   - Able to provide written informed consent
   - Willing to comply with study procedures

---

## EXCLUSION CRITERIA

Patients meeting ANY of the following criteria are NOT eligible:

1. **Secondary Hypertension**
   - Known secondary causes of hypertension
   - History of primary aldosteronism
   - Renovascular hypertension

2. **Cardiovascular Events**
   - Myocardial infarction within 12 months
   - Stroke or TIA within 12 months
   - Unstable angina
   - Heart failure NYHA Class III-IV

3. **Severe Hypertension**
   - SBP ≥180 mmHg or DBP ≥110 mmHg at screening
   - Hypertensive emergency within 6 months

4. **Renal Impairment**
   - eGFR < 30 mL/min/1.73m²
   - History of renal artery stenosis
   - Currently on dialysis

5. **Liver Disease**
   - ALT or AST > 2x upper limit of normal
   - Cirrhosis or chronic liver disease

6. **Diabetes with Poor Control**
   - HbA1c > 10%
   - Diabetic nephropathy with proteinuria > 1g/day

7. **Other Conditions**
   - Pregnancy or nursing
   - Active malignancy
   - Immunosuppressive therapy
   - Participation in another clinical trial within 30 days

---

## Study Duration
- Screening period: Up to 2 weeks
- Treatment period: 24 weeks
- Follow-up period: 2 weeks

## Primary Endpoint
Change from baseline in 24-hour ambulatory systolic blood pressure at Week 12

## Secondary Endpoints
- Change in office blood pressure
- Proportion achieving BP < 140/90 mmHg
- Safety and tolerability
